EcoDrugPlus

Dopamine Receptor D2b

Ensembl ID : ENSIPUG00000022688
Gene Symbol: DRD2B
3 Cross references
141 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSIPUG00000010923
Gene Symbol: DRD3
2 Cross references
203 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSIPUG00000009178
Gene Symbol: DRD4A
2 Cross references
235 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSIPUG00000011011
Gene Symbol: DRD4B
4 Cross references
122 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSIPUG00000021471
Gene Symbol: LOC108264753
3 Cross references
214 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSIPUG00000007773
Gene Symbol: ENPP2
4 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSIPUG00000015883
Gene Symbol: EGLN1
3 Cross references
217 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSIPUG00000023129
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSIPUG00000001099
Gene Symbol: EGLN3
3 Cross references
201 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSIPUG00000007806
Gene Symbol: EPAS1
3 Cross references
148 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSIPUG00000009778
Gene Symbol: EPAS1B
3 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSIPUG00000013220
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).